骨質(zhì)疏松癥-課件_第1頁(yè)
骨質(zhì)疏松癥-課件_第2頁(yè)
骨質(zhì)疏松癥-課件_第3頁(yè)
骨質(zhì)疏松癥-課件_第4頁(yè)
骨質(zhì)疏松癥-課件_第5頁(yè)
已閱讀5頁(yè),還剩23頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、 OsteoporosisLi Mei2015.10.8Osteoporosis8 million Osteoporotic Women and 2.5 million Osteoporotic Men in USAExpected to increase by about 40% by 2020Mortality increased 2-3 fold in women and women after all types of Osteoporotic fractures1 Surgeon-Generals Report2 Canadian and US census data3 Access

2、 Economics, 4 Center 1999Impact of osteoporosis on the quality offragile fractureWhat is the status of diagnose and treat?In study of 4 Midwestern health systems:1/8 1/4 of hip fracture pts received BMD testing were given calcium/D supplements1/10 treated with antiresorptive medicationsUS Department

3、 of Health and Human Services: Bone Health and Osteoporosis: A Report of the Surgeon General, Office of the Surgeon General, 2004.DefinitionSigns and SymptomsMechanismRisk FactorsDiagnosisImportance of BMD testingWho should be tested?BMD testing and interpretationWho should be treated?How to treatme

4、ntOutlineWhat is the definition ? A condition of skeletal fragility characterized by compromised bone strength predisposing to an increased risk of fractureNormal BoneOsteoporosisWhat are the signs and symptoms?Back painLoss of height over timeFractureWhat is the mechanism?Imbalance in bone remodeli

5、ng as a result of: bone breakdown by osteoclasts bone formation by osteblastsBiochemical Markers of Bone TurnoverFormationosteoblastsResorptionosteoclastsFormation Markers Osteocalcin (OC) Bone-specific alkaline phosphatase (BAP) Amino terminal propeptide of type I collagen (PINP) Carboxyl terminal

6、propeptide of type I collagen (PICP)Resorption Markers Pyridinoline (Pyr) Deoxypyridinoline (dPyr) Amino terminal telopeptide of type I collagen (NTX) Carboxyl terminal telopeptide of type I collagen (CTX)How to measure bone mass?FemurWorld Health Organization. Guidelines for Preclinical Evaluation

7、and Clinical Trials in Osteoporosis. Geneva, Switzerland: World Health Organization; 1998.T Score What is the diagnosis criteria?MIBI ScanningMultiple MyolemaBone Biopsy可見(jiàn)大量、增殖的漿細(xì)胞MetastasesMetastasesMetastasisType I Collagen, Osteogenesis Imperfectacollagen“blue” eyes in OIfractures in OICollagen i

8、s the major protein of bone encoded by COLIA1 and COLIA2 genes Collagen genes produce alpha 1 and alpha 2 chains Chains assemble to form collagen fibresMutations cause extreme bone fragility and severeOsteoporosis“brittle bone disease” osteogenesis imperfecta (OI) Antiresorptive Bisphosphonates alen

9、dronate, risedronate, ibandronate, etidronate SERMs (Selective estrogen receptor modulators) raloxifene Estrogen Calcitonin Anabolic PTH Both: Renalate strontiumWhat is the treatments for Osteoporosis?Lifestyle AdviceDietBalanced diet containing adequate calcium1000 mg/dayExerciseRegular weight bear

10、ing exercise 3 times a week for 20 minutes minimumSmokingStop smokingAlcoholWithin safe limits2u/day women3u/day menSunlight Exposure15-20 minutes on face, hands and forearms twice weekly form April to October 基礎(chǔ)用藥 骨吸收抑制劑 骨形成促進(jìn)劑鈣劑 雙膦酸鹽 維生素D 降鈣素 甲狀旁腺素片段 雌激素 合成類(lèi)固醇雷尼酸鍶鹽 雷尼酸鍶鹽 選擇性雌激素受體調(diào)節(jié)劑 維生素K骨質(zhì)疏松防治藥物Ho

11、w to prevent and treat?AgeHormonal ReplacementBisphosphonates StrontiumSERM20406080Vitamin DPTHLife StyleTreatmentchoice* with prev vert fracture(s) * without prev vert fractures * with or without prev verfractures Antifracture efficacy of antiosteoporotic agents 0.61.00.2Incident nonvertebral fract

12、ures Relative risk RLX 60, 120(MORE)*CT 200 (PROOF)* Teriparatide 20g*ALN 5/10 (FIT1)*ALN 5/10 (FIT2)*RIS 5 (VERT-NA)*RIS 5 (VERT-MN)*RIS 2.5/5 (Hip Study)*Incident vertebral fractures Relative risk 0.61.00.2RLX 60 (MORE)*RLX 60 (MORE)*CT 200 (PROOF)* Teriparatide 20g*ALN 5/10 (FIT1)*ALN 5/10 (FIT2)*RIS 5 (VERT-NA)*RIS 5 (VERT-MN)*Strontium ranelate(SOTI)*Strontium ranelate(SOTI +TROPOS)*Strontium ranelate(TROPOS)*Strontium ranelate(SOTI)*Updated from Delmas, Lancet 2002RR 95% CI骨質(zhì)疏松癥治療新藥抗骨吸收藥物DenosumabOdanacatibLasofoxifeneBazedoxifene口服鮭魚(yú)降鈣素 促進(jìn)骨形成藥物骨硬化素抑制劑PTH制劑 經(jīng)皮PTH內(nèi)源性PTH刺激劑 鈣敏感

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論